We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

ADC Therapeutics SA (ADCT) CHF0.064

Sell:$2.80 Buy:$2.82 Change: $0.11 (3.75%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$2.80
Buy:$2.82
Change: $0.11 (3.75%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$2.80
Buy:$2.82
Change: $0.11 (3.75%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Contact details

Address:
Biopole, route de la Corniche 3B
EPALINGES
1066
Switzerland
Telephone:
+41 (21) 6530200
Website:
https://adctherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ADCT
ISIN:
CH0499880968
Market cap:
$275.45 million
Shares in issue:
96.65 million
Sector:
Biotechnology
Exchange:
-
Country:
Switzerland
Currency:
US dollar
Indices:
n/a

Key personnel

  • Ameet Mallik
    Chief Executive Officer, Director
  • Jose Carmona
    Chief Financial Officer
  • Patrick Van Berkel
    Chief Scientific Officer
  • Peter Graham
    Chief Legal Officer
  • Kristen Harrington-smith
    Chief Commercial Officer
  • Michael Mulkerrin
    Chief Technical Operations Officer
  • Mohamed Zaki
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.